Videos

The director of the Parkinson’s Disease and Movement Disorder Center at the University of South Florida detailed the data presented at AAN 2022 and IPX-203’s potential in Parkinson disease. [WATCH TIME: 3 minutes]

Stephen Krieger, MD, spoke about the latest safety data on ofatumumab (Kesimpta; Novartis) and the progress made in novel therapeutics for multiple sclerosis.

Russell Rosenberg, PhD, DABSM, and Margaret Park, MD, review the case of a 15-year-old girl who presents with excessive daytime sleepiness and share clinical impressions on diagnosis and treatment.

The resident physician at Montefiore Medical Center shared her experience with the novel and standardized quick examination tool and the data presented at AAN 2022. [WATCH TIME: 3 minutes]

The professor of neurology at NYU Langone Grossman School of Medicine discussed her talk at AAN 2022 on neurological sequelae and follow-up in hospitalized and nonhospitalized patients with COVID-19. [WATCH TIME: 8 minutes]

The clinical research director of the UCSF Multiple Sclerosis Center discussed new data presented at AAN on inebilizumab (Uplizna; Horizon) in neuromyelitis optica spectrum disorder. [WATCH TIME: 4 minutes]

Robert Zivadinov, MD, PhD, offers his insight into the findings from the DeepGRAI registry of thalamic volume measurement on multicenter clinical-quality T2-FLAIR images in multiple sclerosis.

The Bushell Chair of Neurology at the University of Sydney offered his perspective on phase 2 data of CNM-Au8 in amyotrophic lateral sclerosis and spoke to the advances that the field has made in recent years. [WATCH TIME: 3 minutes]

The pediatric epileptologist from Cleveland Clinic provided commentary on the changes needed to improve research and drug development in CDKL5 deficiency disorder, as well as the organizations committed to advancing the state of care. [WATCH TIME: 3 minutes]

The pediatric epileptologist at Cleveland Clinic discussed the impact of ganaxolone’s approval for CDKL5 deficiency disorder and how it may create an opportunity for future pipeline agents. [WATCH TIME: 3 minutes]

Episode 20 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and Cormac O'Donovan, MD, of Wake Forest Baptist. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending April 2, 2022. [WATCH TIME: 3 minutes]

The Bushell Chair of Neurology at the University of Sydney shared his insight into the latest data on CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis and the frameshift in treatment that it represents. [WATCH TIME: 3 minutes]

The president and chief executive officer of The ALS Association provided insight on the most pressing needs for patients with ALS and the organization’s focus going forward. [WATCH TIME: 5 minutes]

Expert neurologists comment on the impairment of OFF episodes on quality of life for patients and their caregivers.

Key opinion leaders in movement disorders provide insight on factors leading to OFF episodes and how to recognize and mitigate environmental triggers.

Two experts at Jefferson Health discuss several topics related to advances in neurosurgery, technology, and the future of minimally invasive procedures.

Experts in sleep medicine evaluate the impact of narcolepsy on a patient’s quality of life and expand on which symptoms appear to be most debilitating.

Margaret Park, MD, defines typical signs and symptoms of narcolepsy and differentiates between the 2 main types of disease.

The president and chief executive officer of The ALS Association provided insight on the availability of genetic testing for ALS and the organization’s efforts to increase access for the future. [WATCH TIME: 2 minutes]

Klaus Schmierer, MB BS, PhD, FRCP, concludes with advice for community physicians and neurologists who are managing patients with MS and COVID-19 or vaccinations.

Dr Schmierer discusses the general guideline vaccination recommendations for patients with MS.

The president and chief executive officer of The ALS Association highlighted a few of the major developments in the ALS field over the past decade, led by advances in technology. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending March 26, 2022. [WATCH TIME: 4 minutes]

The neurologist and assistant professor at the University of Toronto discussed the different valued biomarkers to assess Alzheimer disease and whether the introduction of retinal imaging changes clinician perception of the most valuable biomarkers. [WATCH TIME: 3 minutes]

The president and chief executive officer of The ALS Association discussed how prevention is being talked about in the ALS community and why it’s no longer a far-off reality. [WATCH TIME: 4 minutes]

Drs Laxman Bahroo and Sanjay Iyer discuss common challenges in identifying OFF episodes in Parkinson disease, the importance of patient education, and utilizing symptom tracking diaries.

Laxman Bahroo, DO, and Sanjay Iyer, MD, define OFF episodes in Parkinson disease and review motor and nonmotor symptoms in patients.

The senior investigator in the Neuromuscular and Neurogenetic Disorders of Childhood Section at NINDS shared his perspective on the data coming out of neuromuscular research and the promise of genetic medicine. [WATCH TIME: 2 minutes]

The president and chief executive officer of The ALS Association provided commentary on the most pertinent issues with managing patients with ALS and the ways to improve current treatment standards. [WATCH TIME: 4 minutes]